"Neutralization Tests" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Descriptor ID |
D009500
|
MeSH Number(s) |
E01.370.225.812.735.550 E05.200.812.735.550 E05.478.594.760.550
|
Concept/Terms |
Neutralization Tests- Neutralization Tests
- Neutralization Test
- Test, Neutralization
- Tests, Neutralization
|
Below are MeSH descriptors whose meaning is more general than "Neutralization Tests".
Below are MeSH descriptors whose meaning is more specific than "Neutralization Tests".
This graph shows the total number of publications written about "Neutralization Tests" by people in this website by year, and whether "Neutralization Tests" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 4 | 4 |
1995 | 0 | 3 | 3 |
1996 | 0 | 4 | 4 |
1997 | 0 | 2 | 2 |
1998 | 0 | 4 | 4 |
1999 | 0 | 5 | 5 |
2000 | 0 | 3 | 3 |
2003 | 1 | 9 | 10 |
2004 | 0 | 6 | 6 |
2005 | 0 | 14 | 14 |
2006 | 0 | 4 | 4 |
2007 | 0 | 8 | 8 |
2008 | 0 | 9 | 9 |
2009 | 0 | 8 | 8 |
2010 | 0 | 5 | 5 |
2011 | 1 | 3 | 4 |
2012 | 0 | 4 | 4 |
2013 | 0 | 9 | 9 |
2014 | 0 | 6 | 6 |
2015 | 0 | 6 | 6 |
2016 | 2 | 6 | 8 |
2017 | 0 | 5 | 5 |
2018 | 1 | 6 | 7 |
2019 | 0 | 2 | 2 |
2020 | 1 | 7 | 8 |
2021 | 1 | 9 | 10 |
2022 | 0 | 9 | 9 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neutralization Tests" by people in Profiles.
-
Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies. Proc Natl Acad Sci U S A. 2023 03 28; 120(13):e2213690120.
-
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerg Microbes Infect. 2022 Dec; 11(1):147-157.
-
Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host Microbe. 2022 11 09; 30(11):1512-1517.e4.
-
Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. Front Immunol. 2022; 13:977064.
-
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Clin Infect Dis. 2022 08 24; 75(1):e827-e837.
-
Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey. mBio. 2022 10 26; 13(5):e0214122.
-
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 07 02; 13(1):3824.
-
Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022 05 27; 13(1):2979.
-
Cryo-EM structure of the SARS-CoV-2 Omicron spike. Cell Rep. 2022 03 01; 38(9):110428.
-
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nat Commun. 2022 01 20; 13(1):405.